Diffuse Large B-Cell Lymphoma (ASH 2022) Basic Listing

Updates in Diffuse Large B-Cell Lymphoma

From the ASH Annual Meeting & Exposition

Conference Coverage

Second-Line Polatuzumab Vedotin Plus RICE Yields High Response Rates in Relapsed/Refractory DLBCL

12/11/2022

Janelle Bradley

Second-line treatment with polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (RICE) yields encouraging responses in patients with relapsed/refractory DLBCL, according to a phase 2 study.

Second-line treatment with...

12/11/2022

Oncology

Diffuse Large B-Cell Lymphoma (ASH 2022) Basic Listing

Specialties

Events

Year Round Education

HMP Global Products